CO
COSM.US Cosmos Health Inc.
- Market cap
- USD 16.3M
- P/E
- -
- P/B
- 1.00x
- ROE
- -86.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is COSM.US undervalued?
Graham numberThe Graham number of Cosmos Health Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cosmos Health Inc. fundamental analysis
No fundamental analysis for Cosmos Health Inc. yet.
Cosmos Health Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cosmos Health Inc.
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), H…
Full company profileCosmos Health Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cosmos Health Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.76M | 30.0M | 37.1M | 39.7M | 55.4M | 56.2M | 50.3M | 53.4M | 54.4M | 65.3M | 73.8M |
| Gross Profit | 601K | 1.96M | 2.41M | 3.66M | 8.06M | 8.33M | 5.96M | 4.35M | 4.31M | 7.90M | 5.79M |
| Operating Income | -203K | -4.87M | -1.23M | -256K | 2.71M | -4.53M | -7.47M | -21.8M | -15.5M | -16.5M | -10.2M |
| EBITDA | -385K | -4.54M | -2.19M | -989K | 4.39M | -4.13M | -8.90M | -17.1M | -13.9M | -15.2M | -12.8M |
| Net Income | -601K | -6.21M | -9.06M | -3.30M | 821K | -7.96M | -13.8M | -18.5M | -16.2M | -19.1M | -17.8M |
| EPS | -1.20 | -12 | -17 | -6.21 | 1.54 | -12 | -7.17 | -1.17 | -0.85 | -0.63 | -0.30 |
| Balance Sheet | |||||||||||
| Total Assets | 3.12M | 10.7M | 20.7M | 23.9M | 43.8M | 49.4M | 68.0M | 66.0M | 54.3M | 65.5M | 61.5M |
| Total Liabilities | 4.87M | 13.7M | 24.0M | 30.3M | 48.0M | 45.0M | 28.4M | 30.0M | 29.8M | 47.1M | 40.8M |
| Shareholders' Equity | -1.75M | -3.03M | -3.32M | -6.46M | -4.16M | 4.38M | 39.7M | 36.0M | 24.5M | 18.4M | 20.7M |
| Cash & Short-term Investments | 717K | 783K | 3.58M | 277K | 851K | 293K | 20.8M | 3.83M | 336K | 762K | 1.84M |
| Total Debt | 3.20M | 10.2M | 16.6M | 19.3M | 32.0M | 27.1M | 12.0M | - | 11.8M | 20.0M | 16.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.13M | -8.76M | -1.56M | -4.79M | -11.5M | -7.10M | -14.9M | -15.6M | -7.72M | -8.45M | -5.57M |
| Capital Expenditure | 12.8K | 55.3K | 503K | 673K | 118K | 891K | 383K | 9.17M | 418K | 55.7K | 150K |
| Free Cash Flow | -2.14M | -8.82M | -2.06M | -5.46M | -11.6M | -7.99M | -15.3M | -24.8M | -8.14M | -8.50M | -5.72M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -181.8% | -34.9% | -51.4% | -66.0% | -103.9% | -86.0% |
| ROA | -19.3% | -58.2% | -43.8% | -13.8% | 1.9% | -16.1% | -20.3% | -28.1% | -29.8% | -29.2% | -28.9% |
| Net Profit Margin | -8.9% | -20.7% | -24.4% | -8.3% | 1.5% | -14.2% | -27.5% | -34.7% | -29.7% | -29.3% | -24.1% |
| Debt to Equity | - | - | - | - | - | 6.19x | 0.30x | - | 0.48x | 1.08x | 0.77x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cosmos Health Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 6.20M | 0.32 | - |
| 2023 | - | - | - |
| 2022 | USD 32.0M | 17 | - |
| 2021 | USD 7.63M | 12 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Nov 13, 2026.
Who owns Cosmos Health Inc.
- Insiders 24.27%
- Institutions 3.75%
- Public & others 71.98%
- Shares outstanding 5.03M
- Free float 3.81M
Top funds holding COSM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 274K | 0.27% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 28.5K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 21.7K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding COSM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| UBS Group AG | 594K | 0.59% | +4,568.31% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 334K | 0.33% | +248.71% | Jun 2026 |
| Jane Street Group LLC | 289K | 0.29% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 282K | 0.28% | -11.32% | Jun 2026 |
| BlackRock Inc | 268K | 0.27% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 174K | 0.17% | +24.26% | Jun 2026 |
| Northern Trust Corp | 53.9K | 0.05% | +162.17% | Jun 2026 |
| State Street Corp | 45.2K | 0.05% | 0.00% | Jun 2026 |
| Sassicaia Capital Advisers LLC | 36.0K | 0.04% | 0.00% | Jun 2026 |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 13.0K | 0.01% | 0.00% | Jun 2026 |
| Park Capital Management, LLC / WI | 12.0K | 0.01% | 0.00% | Sep 2026 |
| SIMPLEX TRADING, LLC | 7.14K | 0.01% | +87.69% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 6.36K | 0.01% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 1.70K | 0.00% | -28.36% | Jun 2026 |
| Hanson Mcclain Inc | 1.24K | 0.00% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 753.00 | 0.00% | -0.26% | Jun 2026 |
| SBI Securities Co Ltd | 299.00 | 0.00% | +166.96% | Jun 2026 |
| Citigroup Inc | 43.00 | 0.00% | -95.66% | Jun 2026 |
| Wells Fargo & Co | 40.00 | 0.00% | 0.00% | Jun 2026 |
| Valley National Advisers Inc | 5.00 | 0.00% | 0.00% | Jun 2026 |
Cosmos Health Inc. company profile
- Company name
- Cosmos Health Inc.
- Ticker
- COSM.US
- Exchange
- USA Stocks
- Listed since
- Oct 11, 2012
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 163
- Fiscal year end
- December
- Address
- 5 Agiou Georgiou Str, Pilea, Thessaloniki, Greece, 55438
- Phone
- 312 536 3102
- Website
- cosmoshealthinc.com
About Cosmos Health Inc.
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.
Cosmos Health Inc. management
5- Mr. Grigorios SiokasChairman & CEO · born 1965
- Mr. Georgios TerzisChief Financial Officer · born 1983
- Mr. Nikolaos BardakisChief Operating Officer · born 1969
- Mr. Demetrios G. DemetriadesSecretary & Independent Director · born 1965
- Prof. Dimitrios TrafalisHead of Oncology